

PE/iFluor™ 594 Anti-human CD40 Antibody
G28.5Catalog number: 104011Y0, 104011Y1, 104011Y2
Unit size: 25 tests, 100 tests, 500 tests**Product Details**

Storage Conditions	2-8°C with minimized light exposure. Do not freeze.
Expiration Date	12 months upon receiving
Concentration	0.1 mg/mL
Formulation	Phosphate-buffered saline (PBS, pH 7.2), 0.09% sodium azide, 0.2% (w/v) BSA

Antibody Properties

Species Reactivity	Human
Class	Primary
Clonality	Monoclonal
Host	Mouse
Isotype	Mouse igg1, κ
Immunogen	CD40 (BP50, TNFRSF5)
Clone	G28.5
Conjugate	PE/iFluor™ 594

Biological Properties

Preparation	Antibody purified by affinity chromatography and then conjugated with PE/iFluor™ 594 under optimal conditions
Application	Flow Cytometry (FACS)

Spectral Properties

Conjugate	PE/iFluor™ 594
Excitation Wavelength	566 nm
Emission Wavelength	606 nm

Applications

G28.5 is an anti-human monoclonal antibody that targets the CD40 antigen. CD40 (also known as Bp50) is a 48 kD transmembrane protein that is expressed on the surface of cells like macrophages, dendritic cells and stem cells. CD40 is a component of key cellular pathways, in particular, the tumor necrosis factor-mediated signaling pathway, immune response-regulating cell surface receptor signaling pathway and CD40 signaling pathway. Also, in many organisms, it upregulates interleukin-12 production, is a positive regulator of isotype switching to IgG isotypes and is a promoter of protein phosphorylation. From a research standpoint, it is of biological interest due to its association with vital

macromolecules/ligands like CD40L, CD154 and TRAP. CD40 is a very popular antibody target, with over 30000 publications in the last decade. CD40 is often used in flow cytometry applications as a phenotypic marker for differentiation of cell types, especially in the study of neuroscience. This antibody was purified through affinity chromatography and conjugated to PE/iFluor™ 594 (ex/em = 566/606 nm). It is compatible with the 561 nm laser and 615/20 nm bandpass filter (for example, as in the Agilent Technologies NovoCyt^e Advanteon).